Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with diffuse large B-cell lymphoma who are not eligible for standard chemotherapy (Abstract S232).
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myelo...
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...
John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerabi...
Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-d...
Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes comp...